Compare · MDT vs QTI
MDT vs QTI
Side-by-side comparison of Medtronic plc. (MDT) and QT Imaging Holdings Inc. (QTI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and QTI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $118.18B, about 2904.4x QTI ($40.7M).
- Over the past year, MDT is down 2.3% and QTI is down 53.8% - MDT leads by 51.5 points.
- MDT has been more active in the news (13 items in the past 4 weeks vs 6 for QTI).
- MDT has more recent analyst coverage (25 ratings vs 0 for QTI).
- Company
- Medtronic plc.
- QT Imaging Holdings Inc.
- Price
- $91.89-0.55%
- $2.76+2.79%
- Market cap
- $118.18B
- $40.7M
- 1M return
- +2.78%
- -1.08%
- 1Y return
- -2.31%
- -53.85%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 13
- 6
- Recent ratings
- 25
- 0
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest MDT
- Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
- Medtronic executives to speak at upcoming investor conferences
- SEC Form 10-Q filed by Medtronic plc.
- SEC Form IRANNOTICE filed by Medtronic plc.
- Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance
- Medtronic Announces Strategic Partnership with Cornerstone Robotics to Further Expand Global Access to Robotic-Assisted Surgery
- Medtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVR
- Needham reiterated coverage on Medtronic with a new price target
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 1,084 units of Ordinary Shares, decreasing direct ownership by 0.92% to 116,336 units (SEC Form 4)
Latest QTI
- iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026
- Chief Executive Officer Dinu Raluca was granted 484,221 shares, increasing direct ownership by 53% to 1,393,066 units (SEC Form 4)
- QT Imaging Holdings Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 4 filed by Director Taylor Ross
- QT Imaging Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- QT Imaging Issues Mid-Year 2026 CEO Letter to Shareholders
- SEC Form 10-Q filed by QT Imaging Holdings Inc.
- QT Imaging Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- QT Imaging Delivers Strong Second Quarter Growth While Building the Foundation for Commercial Scale
- Director Timm Bryan was granted 9,000 shares (SEC Form 4)